%D8%A3%D9%85%D8%A8%D8%B1%D9%8A%D8%B3%D9%8A%D9%86%D8%AA%D8%A7%D9%86Category:AmbrisentanAmbrisentanAmbrisentan%D8%A7%D9%85%D8%A8%D8%B1%DB%8C%D8%B2%D9%86%D8%AA%D8%A7%D9%86AmbrisentanAmbriszent%C3%A1nAmbrisentan%E3%82%A2%E3%83%B3%E3%83%96%E3%83%AA%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%B3AmbrisentanAmbrisentanQ410789
about
sameAs
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial HypertensionStudy to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial HypertensionA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic SclerosisEfficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or FeetThe Effects of Ambrisentan on Exercise Capacity in Fontan PatientsCharacterization and Detection of Prolonged Endothelin Receptors Antagonists AdministrationAn Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)Safely Change From Bosentan to Ambrisentan in Pulmonary HypertensionInfluence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of AmbrisentanEfficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary HypertensionUpfront Combination Pulmonary Arterial Hypertension TherapyDrug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH TherapiesAmbrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label TrialA Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)An Observational Study For AmbrisentanSafety and Efficacy Trial to Treat Diastolic Heart Failure Using AmbrisentanStudy of Ambrisentan in Subjects With Pulmonary HypertensionA Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver CirrhosisAmbrisentan in Single VentricleThe Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension StudyEarly Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)Drug Combination on Exercise Performance at High AltitudeEfficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High AltitudeAmbrisentan for Treatment of Portopulmonary HypertensionThe Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy VolunteersLong-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529Efficacy and Safety of Ambrisentan in Children 8-18yrsExercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With AmbrisentanA Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic SclerosisAmbrisentan (Letairis) for Sarcoidosis Associated Pulmonary HypertensionARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPFA Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)Pharmacogenomics in Pulmonary Arterial HypertensionA Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
P4844
Q1128595-CB11FE82-2BC1-4BA8-AC4B-BA88FC6CADF9Q1128595-EC7B81F3-4357-4CA9-B2B1-7A00DA5444A8Q1131786-1B53AD32-5C19-47CC-84DA-F3F7C9C4E3E2Q124604-B0487EE6-A2FE-442B-A20E-FD98C87EAFC2Q1779300-E2C4BC81-F51E-483B-9565-78B9BA0C4492Q18554296-1DAAA9E0-3BAF-4A35-9149-C16EBF98832EQ5340515-A17BE742-A9C5-41F5-B92D-5BF7F07B9F49Q7232210-877C7A54-D36F-491E-A4F2-0D80430BA663
P2176
Q61921637-B8FC2BE5-45F8-48EC-88B4-56287AB14FE2Q61921663-32971E76-5018-4FC4-AA31-7DE2CBA05FEEQ61921681-D845CDB2-968E-4E3F-85CA-C6636D69077FQ61921707-5512C8B8-3843-49B2-99D9-B8AAE4252914Q61936838-3F5D3BCA-2587-4AF7-AB3D-CC0953FBFE1CQ61938538-C3826097-5776-44A5-BE6C-DD711AA03151Q61975272-A3B2ED5B-CCCB-4474-AC84-EF130F242B19Q63334319-2D0137CD-DCD0-426D-9A07-DDD9BADA67CCQ63335339-7E28A803-3B38-4449-B49B-A50A6BD23FB4Q63338078-006F44AB-4BBE-4AA8-B4C9-F629039268AAQ63339169-0670DE64-902D-4A2F-AD64-54EBB8BAE1B8Q63572150-EF198632-0466-4224-81FE-2E198655A773Q63583891-E87A7747-0317-4D21-90EC-4A070C9B2322Q63806800-CA67DF65-DB3C-4F6E-9D76-A45858174626Q63816637-3A86B1CD-4EFC-4321-95A7-B8ABEF7B3C8DQ63817244-64BD99EA-91EB-4A6E-A8D0-B741D2B6898DQ63829516-0C83632B-4D30-4CD2-A2E1-1DFF9B4950B9Q64046184-E3E178A2-B67A-4067-9B12-184831624AEDQ64170899-D37EB10B-3F03-48BE-9A64-A410C11D4C79Q64170917-94FD0363-D670-4926-917A-DB7816099A45Q64173518-432696BF-7FDE-4FA6-8E1D-3FA79CF3AEACQ64221835-A3C39BDD-9E7D-48BD-80CF-3196B1A644F7Q64601969-B5E16FE1-5C23-425B-811E-50007C67FC85Q64613959-D6B5194E-CEF1-409E-8ECA-C9B22892C5E6Q64623251-E9BE4A64-2344-4818-8E3D-A5E38D333CE9Q64626435-8D055AC1-8270-4A73-8830-48FE646A2239Q64634448-B073AD35-9B36-4B36-B527-505CC805B5C5Q64637406-684B6E99-1885-436C-B40A-DC2E336ED1B9Q64646854-E961D46A-93AC-4D82-ABD4-5D203F2AEC9DQ64650842-AB8FA816-BE71-4960-B9FC-B396D8EFC86BQ64651105-9423BB38-250B-4695-93CA-C454C1D723E2Q64658256-2682FB35-0EE4-499B-9909-D5B5110EDF51Q64659113-95DE1B02-9748-4E14-A625-CF3134D3C6F6Q64679973-3AC2D0A7-47CF-49EA-A6B7-E3B607FB93FBQ64707558-A3428CED-E9F8-4E76-9703-D7056A2EB9C4Q64716236-E1AE67F0-2F21-4119-895E-D0DF6C0BA930Q64718909-12E3EBBC-D281-40E8-BF45-D4CC15DCC1E3Q64723297-5B124009-4274-46BB-B918-400A30177013Q64724826-967260B2-7818-41AD-ABA5-99D47E02C2BDQ64727013-89AACD67-9A53-4545-BD80-2287B1E815A7
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ambrisentan
@de
Ambrisentan
@id
Ambrisentan
@nl
Ambrisentan
@sh
Ambrisentan
@sr
Ambrisentan
@sr-el
Ambrisentan
@vi
Ambriszentán
@hu
ambrisentan
@en
ambrisentan
@fr
type
label
Ambrisentan
@de
Ambrisentan
@id
Ambrisentan
@nl
Ambrisentan
@sh
Ambrisentan
@sr
Ambrisentan
@sr-el
Ambrisentan
@vi
Ambriszentán
@hu
ambrisentan
@en
ambrisentan
@fr
altLabel
(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid
@en
Ambrisentan
@en
C22H22N2O4
@sr
Letairis
@sr
Letairis®
@en
Volibris
@de
Volibris
@sr
prefLabel
Ambrisentan
@de
Ambrisentan
@id
Ambrisentan
@nl
Ambrisentan
@sh
Ambrisentan
@sr
Ambrisentan
@sr-el
Ambrisentan
@vi
Ambriszentán
@hu
ambrisentan
@en
ambrisentan
@fr
P2175
P486
P592
P6366
P646
P661
P662
P683
P117
P2017
CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C